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1
hWeight loss;
Caloric restriction;
Energy metabolismObjective: The purpose of this study was to describe changes in anthropometric
measurements, body composition, blood pressure, lipid profile, and testosterone following
a low–energy-density dietary intervention plus regimented supplementation program.
Methods: The study design was a pre-post intervention design without a control group.
Normal participants were recruited from the faculty, staff, students, and community members
from a chiropractic college to participate in a 21-day weight loss program. All participants
(n = 49; 36 women, 13 men; 31 ± 10.3 years of age) received freshly prepared mostly vegan
meals (breakfast, lunch, and dinner) that included 1200 to 1400 daily calories (5020.8 to
5857.6 J) for the women and 1600 to 1800 (6694.4 to 7531.2 J) daily calories for the men.
Nutritional supplements containing enzymes that were intended to facilitate digestion, reduce
cholesterol levels, increase metabolic rate, and mediate inflammatory processes were
consumed 30 minutes before each meal. The regimented supplementation program included
once-daily supplementation with a green drink that contained alfalfa, wheatgrass, apple cider
vinegar, and fulvic acid throughout the study period. A cleanse supplementation containing
magnesium, chia, flaxseed, lemon, camu camu, cat's claw, bentonite clay, tumeric, pau
d'arco, chanca piedra, stevia, zeolite clay, slippery elm, garlic, ginger, peppermint, aloe, citrus
bioflavonoids, and fulvic acid was added before each meal during week 2. During week 3, the
cleanse supplementation was replaced with probiotic and prebiotic supplementation.
Results: Multiple paired t tests detected clinically meaningful reductions in weight (−8.7 ±
5.54 lb) (−3.9 ± 2.5 kg), total cholesterol (−30.0 ± 29.77 mg/dL), and low-density lipoprotein
cholesterol (−21.0 ± 25.20 mg/dL) (P b .05). There was a pre-post intervention increase in
testosterone for men (111.0 ± 121.13 ng/dL, P b .05).⁎ Corresponding author. New York Chiropractic College, 2360 State Route 89, Seneca Falls, NY 13148. Tel.: +1 315 568 3292; fax: +1
15 3204.
E-mail address: mballiett@nycc.edu (M. Balliett).
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4 M. Balliett, J. R. BurkeConclusions: Weight loss and improvements in total cholesterol and low-density lipoprotein
cholesterol levels occurred after a low–energy-density dietary intervention plus regimented
supplementation program.
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The prevalence of obesity has increased from 11.9%
to 33.4% in men and from 16.6% to 36.5% in women
when comparing the National Health and Nutrition
Examination Survey I study (1971-1975) to the
National Health and Nutrition Examination Survey
2005-2006 data. 1 As summarized by Rolls, 2,3 the
accumulating evidence suggests that the promotion of
diets that reduce the energy density of foods consumed
and address the effects of portion size on the intake of
nutritious low-energy dense foods may be an effective
future strategy to both prevent and treat obesity.
Epidemiological evidence substantiates that consump-
tion of low–energy-density carbohydrates, for exam-
ple, fruits, vegetables, and whole grain products,
positively impacts weight and health even though
clinical trials evidence may be lagging.4 Low–energy-
density diets may allow individuals to more effectively
lose weight, maintain a healthy weight, and prevent
chronic diseases associated with being overweight and
obese to include cardiovascular disease, type II
diabetes, and certain types of cancers. 4-8 In addition,
portion size provides independent and additive effects
of energy density on weight management; and portion
size impacts energy intake for a single meal with the
potential for persistent effects on energy intake over
multiple days. cf 3
Research on vegetarian diets, especially vegan diet,
and the Mediterranean-style diets provides us with
good examples of the impact of consuming nutritious
low-energy dense foods on weight and health. 9-14
Given that adherence to the diet plan is the critical
factor for weight loss, weight maintenance, and health
benefits, health care professionals need to address
individualized eating habits of patients, the effective-
ness of popular weight loss diets, and the cost of
purchasing of foods when making dietary recommen-
dations. 15,16 However, designing energy (calorie)-
restricted diet plans based upon the consumption of
low–calorie-density foods may be able to overcome the
adherence barriers of patient behaviors and dietary
costs. Patient education is emerging as an effective
strategy associated with individuals consuming re-duced-calorie diets. 17-20 Preliminary data on the dietary
costs of nutritious low-calorie dense foods are
beginning to indicate their affordability. 21-23 Other
research is emphasizing the importance of addressing
the effects of food costs on implementing nutritional
interventions for the consumption of healthy foods and
the resultant impact on reducing obesity and disease-
related risk factors. 24-26
In addition to dietary modifications, emerging
evidence suggests a relationship between the microbial
ecology of the gut and obesity. 27-29 Recommendations
for dietary interventions with probiotic and prebiotic
nutritional components suggest that alleviating dysbio-
sis, an imbalance of intestinal bacteria and/or elevated
levels of fungi, may restore the optimal microbial
ecology of the gut. 29-33 Probiotics and prebiotics may
have significant health benefits on lipid metabolism,
mineral absorption, and immune function via their
beneficial influences on microbial ecology of the
gut. 29,31-35 Although there are limited clinical data on
the role of microflora management interventions on
weight loss and improved health status, 36-38 probiotic
and prebiotic nutritional supplementation and colon
cleansing products are being promoted as critical
elements for initiating and maintaining weight loss.
Probiotic and prebiotic nutritional supplements may
evolve into a daily regimen to maintain optimal
microbial ecology of the gut for weight management
and health. 31,32 To date, colon-cleansing products lack
sufficient evidence; but anecdotal recommendations
suggest using colon-cleansing products as a detoxifi-
cation intervention once or twice a year.
In systematic reviews and meta-analyses, dietary
modifications involving either low-carbohydrate foods
or low-fat diets induce weight loss and reduce
metabolic risk factors. 9-14,39 These data suggest that
low–calorie-density diets and caloric restriction may be
the critical elements in weight management programs
regardless of dietary macronutrients. 2,3,15 Designing
and describing calorie-restricted meal plans of low–
calorie-density foods may help health care professions
address the constraints of time, knowledge, and costs of
promoting and/or delivering nutritional interventions as
well as providing their patients with meal plans that fit
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and economic status. Another component of weight
management programs is the use of nutritional
supplements. However, the use of nutritional supple-
ments with and without dietary modifications to
facilitate weight loss and reduce metabolic risk factors
is lacking sufficient evidence. 40 Theories suggesting a
relationship among the microbial ecology of the gut,
weight management, and health indicate an adjunct role
for supplementation in the presence of low–calorie-
density foods. 27-29 Thus, in the current study, a
low–calorie-density dietary intervention with patient
education was used to address various physiologic and
behavioral aspects contributing to the development of a
positive calorie balance that leads to weight gain,2,3,18
whereas the inclusion of nutritional supplementation
was used to target the potential role of gut microbiota in
obesity. 31,32
The purpose of the study was to describe changes in
anthropometric measurements, body composition,
blood pressure, lipid profile, and testosterone following
a low–calorie-density dietary intervention plus regi-
mented supplementation program with patient educa-
tion (21-day treatment intervention program). The
selected outcome measures are some parameters used
to determine if a patient meets the diagnostic criteria for
metabolic syndrome, which increases the risk of
cardiovascular disease, stroke, and type II diabetes. 41Methods
Recruitment and study design
Using a convenience sampling technique, men and
women were recruited from faculty, staff, students,
and community members at a professional school (20-
60 years of age). Participants were recruited by
making announcements in class with the permission
of the class instructor. The principal investigator also
personally contacted members of the faculty and staff
who had expressed an interest in nutritional studies
conducted at the college. The study design was an
observational, pre-post intervention without a control
group or blinding (n = 50). A sample size of 50
participants was estimated to detect a weight loss of
8 lb (3.6 kg) and pre-post differences of 20 mg/dL for
total cholesterol and low-density lipoproteins at 90%
power and a significance level of .05 using paired t
test statistical analyses. All 50 participants participated
in the 21-day treatment intervention program (36women and 14 men). Outcome assessments were
performed at baseline (preintervention) and after the
21-day treatment intervention (postintervention). The
New York Chiropractic College Institutional Review
Board approved all measurement and intervention
procedures for the study. All participants provided
written informed consent.Exclusion criteria
Individuals that were pregnant; were nursing; had a
pacemaker; and were on medications for hypertension
(such as a diuretic, angiotensin-converting enzyme
inhibitor, or calcium channel blocker), cholesterol
(such as a statin drug), or diabetes (such as
metformin) were excluded from the study. Individuals
with any food allergy or with known allergies to any
of the supplement ingredients were excluded. In-
dividuals with any digestive disorders such as Crohn
disease or ulcerative colitis as well as individuals
who had undergone any surgery to the gastrointes-
tinal system including, but not limited to, hiatal
hernia surgery, bariatric surgery, lap band, and/or
colostomy were excluded. Individuals with any
diagnosed blood disorder including, but not limited
to, anemia, low platelet count and clotting disorder
were excluded. In summary, individuals on any
prescribed medications, except birth control pills,
over-the-counter medications, vitamins, or supple-
ments, were excluded.
In addition, screenings of blood pressure and body
mass index (BMI) occurred at the first laboratory visit.
Measurements of sitting blood pressure were from
both arms using the standard clinic procedure of
mercury sphygmomanometer with the Korotkoff
sound technique according to the recommendations
for blood pressure measurements in humans.42 The
exclusion criteria used for blood pressure were a
systolic blood pressure of at least 150 mm Hg and/or
diastolic blood pressure of at least 95 mm Hg.
Participants were allowed to participate with mild
unmedicated hypertension (N140/90 mm Hg) because
of the potential effects of the 21-day intervention
program on reducing blood pressure associated with
weight loss and improvements in lipid profiles. Blood
pressure was measured at the postintervention labora-
tory visit both as an outcome measure and to advise
participants on their current blood pressure status.
Participants with a calculated BMI of less than 20 kg/m2
were excluded for being underweight (cf anthropo-
metric measurements below).
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All participants received prepared meals for 21 days,
delivered every day or every other day, and on Fridays
for the weekends. The company supplying the food
(5 Squares, New Rochelle, NY) provided food, local and
organicwhen available; and themenuwas predominately
vegan after the first few days. Meal plan and recipes are
available upon request from the principal investigator.
The low–calorie-density diet had on average 1200 to
1400 daily calories (5020.8 to 5857.6 J) for the female
participants and 1600 to 1800 daily calories (5594.4 to
7531.2 J) for the male participants. Participants were
instructed to maintain their normal amount of daily
physical activities and not to engage in exercise beyond
20 minutes of walking, yoga, or tai chi.
The regimented supplementation program was
divided into 3 weekly phases: Reclaim, Release, and
Restore (Ultimate Reset Beachbody, Santa Monica,
CA). The regimented supplementation program is
summarized below.
The supplementation regimen during the Reclaim
week (week 1) was as follows:• Thirty minutes before breakfast, lunch, and dinner,
participants drank 12 to 24 oz of distilled water
(which was provided) with a “pinch” of Himalayan
salt, consumed 10 to 15 drops of a liquid oxygen
supplement, and swallowed 2 systemic enzyme
capsules containing protease/bromelain, serrapep-
tase, papain, amylase, lipase, rutin, amla, maltosex-
trin, methylsulfonylmethane, and camu camu.
• At least 2 hours after lunch, participants drank 12 to
24 oz of distilledwater with a “pinch” ofHimalayan
salt and another 4 to 8 oz of distilled water mixed
with 3 g of alkalinizer powder (“green food”:
alfalfa, wheatgrass, apple cider vinegar, fulvic
acid). After waiting 30 minutes, participants were
allowed to consume a snack consisting of unsalted
almonds and/or apples. The participants purchased
these snack foods for themselves.
• The participants waited a minimum of 2 hours
after consuming the alkalinizer supplement or
snack to consume their dinner supplements (12-
24 oz of distilled water with a “pinch” of
Himalayan salt, liquid oxygen, and systemic
enzymes). Then 30 minutes later, participants
consumed their dinner.
During the Release week (week 2), the participants
followed the same regimen as the Reclaim week (week1). However, in addition to theReclaim premeal regimen,
participants drank 8 to 12 oz of distilledwater mixedwith
10 g of detoxify powder (magnesium, chia, flaxseed,
lemon, camu camu, cat's claw, bentonite clay, tumeric,
pau d'arco, chanca piedra, stevia, zeolite clay, slippery
elm, garlic, ginger, peppermint, aloe, citrus bioflavo-
noids, and fulvic acid) 30 minutes before each meal.
During the Restore week (week 3), the participants
followed the same regimen as the Reclaim week (week
1). However, in addition to the Reclaim premeal regime,
participants swallowed 2 capsules of a prebiotic/
probiotic supplement containing LactoSpore (Bacillus
coagulans; Sabinsa, Payson, UT) and yacon 30 minutes
before breakfast, lunch, and dinner. The prebiotic/
probiotic supplement was added after the colon cleanse
to enhance any potential impact of the prebiotic/
probiotic agents on restoring optimal microbial ecology
of the gut.
During the 21-day treatment intervention, partici-
pants were allowed to drink additional amounts of
distilled water throughout the day and with their meals.
Participants were asked to refrain from drinking other
types of beverages including, but not limited to, coffee,
tea, alcohol, soda, milk, or juice.
Data collection
Anthropometric measurements included body
weight, height, BMI, and waist and hip circumferences.
Anthropometric assessments were conducted with the
participants wearing light clothing (gown and shorts)
and barefoot. Weight was measured using a high-
precision digital scale (DI-10, DIGI Matex, Inc,
Singapore; 0.1-kg gradations, 225-kg capacity). Height
wasmeasured using a high-precision digital stadiometer
(seca 242, Hamburg, Germany; 1-mm gradations;
measuring range, 62-210 cm). Body mass index was
calculated from the measured body weight and height
(kilograms per square meter). A standard cloth tape
measure was used to record waist and hip circumference
in inches. The clinician measured the circumferences of
each site at least 3 times and averaged the 3 most
consistent measurements to enhance reliability. Body
landmarks of the umbilicus and greater trochanters were
used to standardize measurements of pre-post waist and
hip circumferences, respectively, to enhance reliability
and validity. The waist-to-hip ratio and waist-to-height
ratio were calculated.
Body composition was estimated using bioelectrical
impedance analysis (BIA) (Biomarkers 2000 Body
Scan Analyzer, Biodynamics Corporation, Seattle,
WA). The validity of BIA as compared with dual-
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sition exhibited high relative agreement in normal-
weight, overweight, and obese individuals. 43-45 The
regression analysis of BIA and dual-energy x-ray
absorptiometry method to measure fat mass at baseline
and then at 6 and 12 months after bariatric surgery in
premenopausal morbidly obese women was 0.98, 0.94
and 0.99, respectively. 46 The Biomarkers 2000 device
uses the wrist-ankle electrode arrangement, which is
convenient, is easy to use, and yields accurate results
for participants in the normal-weight, overweight, and
obese categories relative to BMI or body fatness. 47-49
Participants came to the laboratory after an overnight
fast and 24 hours without exercising and consuming
alcohol or stimulant beverages. The participants were
lying supine on a stationary massage table (Earthlite,
Vista, CA) in a relaxed position with their feet 12 to 18
in apart, their upper-inner thighs spread far enough
apart so that they did not touch each other, their hands
no more than 6 in from their sides, and their upper-inner
arms not touching the torso. Electrodes (25 mm ×
25 mm, Ag-Ag Cl, SilveRest, Bellows Falls, VT) were
placed on the right hand and right foot according to the
manufacturer's guidelines and the traditional supine
arm-to-leg BIA method. Predictive models for total
body water, fat mass, and fat-free mass (lean body
mass) and their percentages, as well as percentages of
intracellular water and extracellular water, were
calculated from measurements of resistance and
reactance values based on the preprogrammed algo-
rithms accompanying the BIA instrument that incor-
porated the measured weight, height, sex, and age.
Although measurement procedures for BIA met all
standards to ensure accuracy, BIA only provides an
estimate of body composition. 43,45,47,48
Fasting lipid profile and testosterone were obtained
from each participant pre-post diet intervention.
Professional services were obtained from a local
hospital to perform the blood draws and analyze the
venous plasma samples. Venous plasma (lithium
heparin) was collected by standard venipuncture
technique from the antecubital vein. Venous plasma
samples were analyzed using routine clinical chemistry
methods to measure total cholesterol, low-density
lipoproteins (LDL cholesterol), high-density lipopro-
teins (HDL cholesterol), triglycerides, and testosterone.
Statistical analyses
Pre-post intervention data from the anthropometric
measurements, lipid profile, blood pressure, and body
composition estimations were compared using pairedt tests for each dependent variable. A sex by time mixed
analysis of variance model was used to detect changes
in testosterone pre-post intervention as a function of sex.
Treatment integrity and adverse events were described
qualitatively from the weekly diaries. Intention-to-treat
analyses were used to account for participants that
withdrew from participation. The level for each
statistical procedure was 0.05. There was no correction
for multiple dependent variables, for example, experi-
ment-wise error rate.Results
Study population
During a period of 1 week, we recruited 52
participants to participate in the research study. Two
of these participants were excluded for having high
blood pressure. The remaining 50 patients were
enrolled into the research study. Upon completion of
the preintervention blood analyses, 1 participant was
withdrawn from the study by the principal investigator.
Although this participant did not satisfy any exclusion
criteria at the time of enrollment, an underlying medical
condition was diagnosed from blood analyses; and the
participant was appropriately referred for medical
treatment. The preintervention data points for this
participant were deemed outliers and excluded from the
statistical analyses.
Six other participants dropped out of the study. One
of these participants withdrew from the study because
of an adverse reaction of hives, nausea, and vomiting to
the consumption of the Reclaim supplements during
week 1. After the first week, 2 participants withdrew
because they were unable to pick up their prepared
meals because of personal circumstances that arose
after enrolling in the study. During the second week, 1
participant withdrew from the study because of being
“too hungry” to continue on the low-calorie diet. After
week 2, two participants withdrew from the study
because they were not being compliant with the 21-day
intervention program. Forty-three participants success-
fully completed the study protocol. Dependent vari-
ables were analyzed using the intention-to-treat
approach, which assumed the same pre-post values
for the 6 participants who withdrew from the study. The
total number of participants included in the paired t test
analyses was 49 (36 women, 13 men; 31 ± 10.3 years of
age) based upon intention-to-treat approach and the
removal of the 1 participant with the undiagnosed
underlying medical condition at enrollment.
Table 1 Compliance with dietary menu—additional
food consumed (percentage of person days)
Types of food
Week 1
(n = 48)
Week 2
(n = 45)
Week 3
(n = 43)
Apples 40 43 44
Almonds 42 50 45
Protein 6 11 22
Fruits/vegetables 2 6 11
Carbohydrates 6 10 12
Refined sugar 4 5 5
Tap water 0 1 1
Coffee/caffeine 8 6 7
Alcohol 2 0 1
Dairy 1 0 1
Protein included eating other nuts besides almonds or animal
protein sources excluding dairy. Carbohydrates included bread,
potatoes, or pasta. Refined sugar included any type of dessert.
Dairy included fluid milk, cheese, or yogurt.
Table 2 Compliance with 21-day intervention program
(percentage of person days)
Category
Week 1
(n = 48)
Week 2
(n = 45)
Week 3
(n = 43)
Consumed all meals
and supplements
58 70 60
Did not consume all the
breakfast with provided
supplements
7 7 5
Did not consume all the lunch
with provided supplements
14 9 15
Did not consume all the dinner
with provided supplements
20 12 17
Did not consume the alkalinizer
between lunch and dinner
1 2 3
Table 3 Blood pressure (mean values ± SD, mm Hg)
Preintervention Postintervention Difference
Right arm
Systolic 116 ± 9.4 112 ± 8.8 −4 ± 6.7 *
Diastolic 76 ± 9.9 71 ± 8.0 −5 ± 8.4 *
Left arm
Systolic 116 ± 9.4 112 ± 7.9 −4 ± 6.3 *
Diastolic 76 ±10.1 72 ± 7.8 −4 ± 7.8 *
* Significant at P b .05.
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Tables 1 and 2 summarize compliance to the dietary
menu and the 21-day intervention program. Data are
expressed as a percentage of person days for each
week. Person days for each week were the number
participants participating multiplied by 7 days. From
the weekly diaries of all participants, each occurrence
of noncompliance was categorized as shown in Tables 1
and 2; and then the total of noncompliance occurrences
was expressed as the percentage of person days.
Throughout the 21-day intervention program, partici-
pants consumed the allowed snack option of apples
and/or almonds at frequencies between 40% and 50%.
The addition of protein sources to the dietary menu
increased throughout the 21-day intervention program
from 6% to 22%. The consumption of additional fruits,
vegetables, and other carbohydrate sources alsoincreased from 2% to 6% during week 1 to 11% to 12%
during week 3. The frequencies of consumption of
coffee and caffeine and refined sugars were maintained
throughout the study at 6% to 8% and 4% to 5%,
respectively. The participants refrained from alcohol
consumption throughout the 21-day intervention pro-
gram, as the frequency of consumption was only 1%
to 2%.
Adherence to the 21-day intervention program, both
dietary menu and regimented supplementation pro-
gram, occurred at an average weekly frequency of 63%.
Noncompliance with the 21-day intervention program
at breakfast, lunch, and dinner occurred at average
weekly frequencies of 6%, 13%, and 16%, respectively.
The participants consumed the alkalinizer supplement 2
hours after lunch, as the noncompliance frequency was
only 1% to 3%.
Outcome measures
The 21-day intervention program decreased blood
pressure from 116/76 to 112/72 mm Hg (Table 3, P b
.05). There were pre-post intervention decreases in
weight (−8.7 ± 5.54 lb; −3.9 ± 2.5 kg), BMI (− 1.4 ±
0.81 kg/m2), waist circumference (−1.5 ± 1.14 in), hip
circumference (−1.2 ± 1.24 in), waist-to-hip ratio (−
0.01 ± 0.033), and waist-to-height ratio (−0.02 ± 0.018)
(Table 4, P b .05). Pre-post intervention decreases in
levels of total cholesterol (−30.0 ± 29.77 mg/dL), LDL
cholesterol (−21.0 ± 25.20 mg/dL), HDL cholesterol
(−6.9 ± 9.43 mg/dL), and triglycerides (−10.1 ± 34.66
mg/dL) occurred (Table 5, P b .05). There was a pre-
post intervention increase in testosterone for men
(111.0 ± 121.13 ng/dL) without a concomitant
change for women (Table 6, F1,47 sex × time =
28.48, P b .05). Pre-post intervention decreases
occurred for fat mass (−5.2 ± 4.12 lb; −2.4 ± 1.9
kg) and fat-free mass (−4.0 ± 4.16 lb; −1.8 ± 1.9 kg)
with an increase in percentage of fat-free mass (+1.5%
± 1.88%) (Table 7, P b .05). Other estimates of body
composition from the BIA did not change pre-post
intervention (Table 7, P N .05).
Table 4 Anthropometric measurements (mean values ± SD)
Preintervention Postintervention Difference
Weight (lb) 175.4 ± 38.31 166.7 ± 36.69 −8.7 ± 5.54 *
(7.16-10.34)
Waist (in) 36.4 ± 5.74 34.9± 5.81 −1.5 ± 1.14 *
(1.13-1.78)
Hip (in) 42.0 ± 3.93 40.8 ± 3.71 −1.2 ± 1.24 *
(.80-1.51)
Waist-hip ratio 0.86 ± 0.081 0.85 ± 0.087 −0.01 ± 0.033 *
(.002-.021)
Height (in) 66.23 ± 2.946 66.25 ± 2.936 N/A
Waist-height ratio 0.55 ± 0.087 0.53 ± 0.088 −0.02 ± 0.018 *
(0.017-0.027)
BMI (kg/m2) 28.0 ± 5.29 26.6 ± 5.09 −1.4 ± 0.81 *
(1.2-1.6)
* Significant at P b .05; 95th confidence intervals of the difference in parentheses.
9Portion size, energy density, and weight lossAdverse effects
Table 8 summarizes the frequency of adverse
effects. The most common adverse effect was head-
ache, which occurred at a frequency of 22% during
week 1. Headaches subsided during weeks 2 and 3 and
occurred at frequencies of 8% and 3%, respectively.
The headaches appeared to be due to withdrawal from
caffeine during week 1. During week 3, participants did
report an increase in fatigue, which occurred at a
frequency of 12%. The increase in fatigue was
attributed to being on a low-calorie diet for 3 weeks.
From week 1 to week 3, frequency of participants
reporting no adverse effects increased from 55% to
66% to 72%.Discussion
The observational study indicated that a low–
calorie-density dietary intervention plus regimented
supplementation program with patient education im-Table 5 Fasting hemoglobin A1c levels and lipid profile data
Preintervention
Total cholesterol (mg/dL) 185.0 ± 39.58
HDL (mg/dL) 63.7 ± 15.77
LDL (mg/dL) 102.7 ± 36.92
Triglycerides (mg/dL) 93.1 ± 47.41
* Significant at P b .05; 95th confidence intervals of the differenceproved weight status and lipid profiles. As discussed
below, clinically meaningful differences occurred for
weight loss, total cholesterol, and LDL cholesterol
following the 21-day intervention program. Improve-
ments in weight status, total cholesterol, and LDL
cholesterol decrease the risk of metabolic syndrome
and associated disease states, including, but not limited
to, cardiovascular disease, stroke, and type II diabe-
tes. 41 For men, a clinically meaningful improvement in
testosterone levels was observed pre-post intervention.
Adverse effects were tolerable, and adherence to the
21-day intervention was acceptable.
The participants experienced a weight loss of 8.7 lb
(3.9 kg), on average, over a 21-day period, which was
slightly less than the rapid weight loss recommenda-
tions of approximately 2% to 3% of initial body weight
per week for overweight and obese adults under the
supervision of a health care provider50-53 and slightly
greater than the weight loss guidelines of the
Department of Health and Human Services of 1 to 2
lb per week.54 Although BMI significantly decreased
from 28.0 ± 5.29 to 26.6 ± 5.09 kg/m2 after the 21-day(mean values ± SD)
Postintervention Difference
155.0 ± 29.18 −30.0 ± 29.77 *
(21.4-38.5)
56.8 ± 13.71 −6.9 ± 9.43 *
(4.3-9.7)
81.7 ± 24.40 −21.0 ± 25.20 *
(13.7-28.2)
83.0 ± 30.86 −10.1 ± 34.66 *
(0.1-20.0)
in parentheses.
Table 6 Testosterone (in nanograms per deciliter) by sex (mean values ± SD)
Preintervention Postintervention Difference
Women 32.5 ± 12.82 32.5 ± 22.97 0.0 ± 22.91
(−7.7 to +7.8)
Men 400.8 ± 125.06 511.8 ± 188.06 +111.0 ± 121.13 *
(37.8-184.2)
* Significant at P b .05; 95th confidence intervals of the difference in parentheses.
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overweight category pre-post intervention. Waist-to-
hip ratio and waist-to-height ratio are other indices of
improvements in weight status and discriminators of
cardiovascular risk factors. The recommended waist-to-
hip ratios, which are associated with a decreased risk
for cardiovascular disease, are less than 0.83 for women
and less than 0.90 for men.55 Pre-post changes in the
waist-to-hip ratios were not clinically meaningful, as
both the men (0.92 to 0.91) and women (0.84 to 0.83)
remained in the at-risk category throughout the study
period. Similarly, the decrease in the waist-to-height
ratio from 0.55 to 0.53 was not deemed clinically
meaningful because waist-to-height ratios less than
0.50 are associated with a decreased risk for cardio-
vascular disease. 56,57
Normative values from the National Cholesterol
Education Program were used to define clinically
meaningful differences in cholesterol levels. 58,59
Although total cholesterol levels were less than the
National Cholesterol Education Program target level of
200 mg/dL at preintervention (185 mg/dL), the pre-post
intervention decrease of 30 mg/dL was still deemed
clinically meaningful, as a total cholesterol level of 155
mg/dL after the 21-day intervention program reflects a
more favorable lipid profile. The preintervention LDLTable 7 Estimates of body composition (mean values ± SD)
Preintervention Postintervention Difference
Total body water (L) 40.3 ± 8.91 38.9 ± 8.18 −1.4 ± 1.74 *
(.9-1.9)
Intracellular water (%) 55.2 ± 4.10 55.6 ± 4.57 +0.4 ± 2.25
(−1.0 to +0.3)
Extracellular water (%) 44.8 ± 4.10 44.8 ± 4.71 0.0 ± 2.84
(−0.8 to + 0.8)
Fat mass (lb) 52.4 ± 21.02 47.2 ± 20.36 −5.2 ± 4.12 *
(4.0-6.4)
Fat mass (%) 29.3 ± 7.11 28.3 ± 8.96 −1.0 ± 4.39
(−0.3 to +2.2)
Fat-free mass (lb) 123.2 ± 25.11 119.2 ± 23.77 −4.0 ± 4.16 *
(2.9-5.2)
Fat-free mass (%) 70.7 ± 7.11 72.2 ± 7.45 +1.5 ± 1.88 *
(1.0-2.0)
* Significant at P b .05; 95th confidence intervals of the difference in parentheses.cholesterol levels of 103 mg/dL decreased by 21 to 83
mg/dL after the 21-day intervention program. This pre-
post intervention decrease is clinically meaningful
within the context of LDL cholesterol levels being less
than 100 mg/dL as ideal for reducing the risk of
cardiovascular disease and the most recent recom-
mendation to change the ideal target to less than
70 mg/dL.59 Despite the significant decreases in
triglycerides and HDL cholesterol levels pre-post
intervention, both lipid profile indices were at optimal
or near-optimal levels throughout study period, less
than 100 mg/dL for triglycerides and less than 60 mg/
dL for HDL cholesterol. In addition, a decrease in HDL
cholesterol is expected when participants are partici-
pating in a calorie-restricted, low–calorie-density
dietary intervention. 60,61
In agreement with previous literature on low–
calorie-density diets and portion size restriction, 2,3
improvements in total cholesterol and LDL cholesterol
levels occurred concomitantly with weight loss after the
21-day intervention program. The low attrition rate of
14% with adequate adherence to the 21-day interven-
tion program was most likely due to the ease of
consuming quality, portion-controlled meals and nutri-
tional supplements with the support of coaching and the
short duration of the intervention. 62-65 However, the
Table 8 Adverse effects (percentage of person days)
Adverse effects
Week 1
(n = 48)
Week 2
(n = 45)
Week 3
(n = 43)
Headache 22 8 3
Dizziness 1 2 2
Fatigue 6 4 12
Constipation 1 5 3
Hunger 2 2 2
Nausea 4 5 0
Loose stool 3 1 2
Cold/chilled 1 1 0
Gassy/cramps 1 3 0
Allergic-type reaction 1 2 1
Enlarged lymph nodes 1 1 0
Muscle cramps 1 0 3
Loss of appetite 1 0 0
No symptoms 55 66 72
11Portion size, energy density, and weight lossprogressive increase in the consumption of foods high
in protein, which was in addition to meals provided and
included eating other nuts besides almonds or animal
protein sources excluding dairy, suggests that a low–
calorie-density dietary intervention needs to maintain
adequate levels of dietary protein for many individuals.
In support of this suggestion, 66 the 21-day intervention
program induced a decrease in fat-free mass of 4 lb (1.8
kg), 3 lb (1.4 kg) due to water loss and 1 lb (0.4 kg) due
to muscle loss, as well as inducing a 5-lb (2.3 kg)
decrease in fat mass. Increasing protein intake during
the 21-day intervention program may be necessary to
prevent the loss of muscle mass, as the literature
suggests that high-protein weight loss diets reduce fat
mass while maintaining lean body mass.66-70 Intracel-
lular and extracellular water percentages were within
normal limits pre-post intervention. 45
Among men, there is an inverse relationship between
weight status indices, BMI, and waist circumference,
and serum testosterone levels (r = − .45). 71-73 Further-
more, serum testosterone levels between 450 and
600 ng/dL are associated with decreased risk for
cardiovascular disease, type II diabetes mellitus, and
metabolic syndrome. cf 73 Although more conclusive
evidence is needed,73 increases in serum testosterone
levels of 11% to 24% have been shown to accompany
weight loss from restricted calorie diets in obese
men.74,75 In the current study, the 28% increase in
serum testosterone levels from 400.8 to 511.8 ng/dL for
men was consistent with previous reports on weight
loss with a restricted-calorie diet and reflected a
clinically meaningful difference with respect to reduc-
ing the risk for chronic diseases. Despite having only
13 men in the study, the correlation between pre-postinvention changes in serum testosterone levels and
BMI was r = − .44. Among our female participants,
serum testosterone levels were within the reference
range, 8 to 60 ng/dL, at preintervention and did not
change after the 21-day intervention program.
Limitations
As an observational study, the lack of blinding,
randomization, and a control group limits the generaliz-
ability of the results. Participant selection bias limits the
generalizability of the results. Participants only logged
compliance with the consumption of preparedmeals plus
regimented supplementation program, and the return of
the supplement products was not required. Thus, our
adherence data may be inflated. The multicomponent
nature of dietary intervention plus regimented supple-
mentation program with coaching and no control group
precludes us from making specific recommendations on
the use of nutritional supplements such as (1) probiotic
and prebiotic nutritional supplementation and colon-
cleansing products as critical elements for initiating and
maintaining weight loss or (2) nutritional supplements
containing enzymes to facilitate digestion, reduce
cholesterol levels, increase metabolic rate, and mediate
inflammatory processes. However, according to current
empirical recommendations, the colon-cleanse product
was used during the initial stages of a weight loss
program; and the nutritional supplements, for example,
enzymes, prebiotics and probiotics, were used daily.
Future studies need to address the potential additive
effects of supplementation programs, that is, independent
of dietary interventions alone, on weight loss, weight
maintenance, and lipid profiles.Conclusion
Weight loss and improvements in total cholesterol
and LDL cholesterol levels occurred after a low–
calorie-density dietary intervention plus regimented
supplementation program.Funding sources and potential conflicts
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